Presentation is loading. Please wait.

Presentation is loading. Please wait.

Influenza Vaccine Manufacturing Industry Perspective for 2014-15 NH Vaccine Supply The FDA CBER requested this annual summary of information from influenza.

Similar presentations


Presentation on theme: "Influenza Vaccine Manufacturing Industry Perspective for 2014-15 NH Vaccine Supply The FDA CBER requested this annual summary of information from influenza."— Presentation transcript:

1 Influenza Vaccine Manufacturing Industry Perspective for NH Vaccine Supply The FDA CBER requested this annual summary of information from influenza vaccine manufacturers supplying the U.S., for purposes of a general presentation to the VRBPAC. This summary has been prepared from a variety of public sources, and was reviewed by AstraZeneca, bioCSL, GSK, Novartis, Protein Sciences, and Sanofi Pasteur.

2 Influenza Vaccines ~134 million doses distributed through 31 January 2014 and in line with season 1 Transition to quadrivalent influenza vaccine (QIV) began during season with QIV volume ~20% of total doses QIV volume will likely increase to over 50% for the season As the variety of influenza vaccines has increased in recent years, healthcare providers are choosing different presentations for different patients Timely strain selection by VRBPAC in February 2013 was very helpful Challenges A(H3N2) recommendation was an H3N2 virus antigenically like the cell- propagated prototype virus A/Victoria/361/2011 (clarified for WHO 2014 SH and NH recommendations) Industry Comments, VRBPAC 28 February Source: 1 (as of 12 Feb 2014)http://www.cdc.gov/flu/professionals/vaccination/vaccinesupply.htm

3 Vaccination Rates in Higher than in Overall immunization rate of 45% for individuals 6 months of age and older during the season Significant increase in the 6 months - 17 years of age group (to 56.6%) Slight increase in the 18 years of age and older group (to 41.5%) Source: (as of 12 Feb 2014)http://www.cdc.gov/flu/fluvaxview/coverage-1213estimates.htm Industry Comments, VRBPAC 28 February 2014

4 Total Cumulative Influenza Vaccine Claims in Higher than in Source: IMS Health Custom Study, Medical Claims Data, Week Ending 25 Jan 2014 ~6% Data suggest immunizations are up ~6% vs. prior year Industry Comments, VRBPAC 28 February 2014

5 Influenza Vaccine Strain Changes SeasonA(H1N1)A(H3N2)B-VicB-YamComment First selection for QIV n/a n/a No strain change n/a n/a n/a Three strain changes n/a n/a n/a n/a n/a No strain change n/a n/a 5 Industry Comments, VRBPAC 28 February 2014

6 Influenza Vaccine Manufacturing Timeline JanDecNovFebMarAprMayJunJulAugSepOct Surveillance & Reassortants Vaccination Distribution Filling & Packaging Formulation Produce Working Seed Annual License Approval Production (may be at risk) Production 4 Strain Balancing 4 4 FDA Strain Selection Produce & Standardize Reagents Production (at risk) 6 Industry Comments, VRBPAC 28 February 2014

7 Influenza Vaccine Manufacturing Critical Factors Global timing of strain selection ensures large vaccine supply Available time to manufacture influenza vaccine is determined by Need to distribute & administer vaccine well before the peak season Availability of last vaccine strain To ensure timely availability of influenza vaccine, manufacturing of at least one strain starts at risk before VRBPAC recommendations Productivity of the least productive monovalent strain determines supply quantity Availability of potency test reagents Complex process to prepare and standardize potency reagents for new strains Linked to global timing of strain selection for new strains Availability of calibrated reagents determines start of influenza vaccine formulation 7 Industry Comments, VRBPAC 28 February 2014

8 Vaccine Strains under Evaluation for NH Vaccine A(H1N1): A/California/7/2009-like A/California/7/2009 and reassortants (IIV and LAIV) A/Christchurch/16/2010 and reassortants (IIV) A/Brisbane/10/2010 and reassortants A(H3N2): A/Victoria/361/2011 cell-derived-like A/Texas/50/2012 and reassortants (IIV and LAIV) A/New York/39/2012 and reassortants A/Almaty/2958/2013 and reassortants 8 Industry Comments, VRBPAC 28 February 2014

9 Vaccine Strains under Evaluation for NH Vaccine B Yamagata lineage B/Massachusetts/2/2012 and reassortants (IIV and LAIV) B Victoria lineage B/Brisbane/60/2008 and reassortants (IIV and LAIV) B/Hong Kong/259/2010 and reassortants (IIV) B/Nevada/3/2011 and reassortants (IIV and LAIV) B/Texas/2/2013 and reassortants 9 Industry Comments, VRBPAC 28 February 2014

10 Industry Agency Shared Responsibility for Successful Influenza Vaccine Production & Supply Communication Continued timely sharing of surveillance and candidate virus information Bi-weekly WHO teleconferences key in challenging situations Strain selection Timely review and selection of the appropriate viral strains Balanced consideration of strain surveillance, selection timing, and impact to vaccine availability Virus and reagent availability Early access of all reassortant labs (NYMC, NIBSC, bioCSL, AstraZeneca, etc) to wild-type viruses Opportunity for manufacturers to evaluate growth characteristics of potential strain candidates Availability of potency test reagents for new strains by June Vaccine approval and release Timely approval of annual license supplement In-season lot review and release process 10 Industry Comments, VRBPAC 28 February 2014


Download ppt "Influenza Vaccine Manufacturing Industry Perspective for 2014-15 NH Vaccine Supply The FDA CBER requested this annual summary of information from influenza."

Similar presentations


Ads by Google